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Percutaneous pulmonary valve implantation had been used for over ten years. This study 
was aimed to analyze clinical outcomes after percutaneous pulmonary valve implant by 
systematic review and meta-analysis of preexisting published studies. Method 
Literature search was performed on April 2014 via PubMed and Cochrane database 
using NECA guideline. Out of 599 studies 10 published articles since 2005 were eligible 
to be included in this study. Meta-analysis was performed using RevMan. Result 
Significant efficacy was shown via pooled immediate hemodynamics, MRI, 
regurgitation outcomes. RV systolic pressure was significantly decreased (mean 
difference: 20.03mmHg, 95%: 17.95, 12.11). RV diastolic pressure was decreased (mean 
difference: 1.69mmHg, 95%: 0.94, 2.26). RV-PA gradient was reduced (mean difference: 
18.96, 95%: 15.94, 21.99). End-diastolic RV volume was significantly reduced (mean 
difference: 26.92, 95%: 16.06, 37.77). Conclusion This study shows clinically 
significant improvement in safety and efficacy percutaneous pulmonary valve 
implantation.  
 
Keywords : percutaneous pulmonary valve implantation, transcatheter 
pulmonary valve implantation, systematic review, meta-analysis 




I. INTRODUCTION ................................................................................................................. 1 
II. BACKGROUND .................................................................................................................... 2 
2.1 Right Ventricular Outflow Tract Disease .............................................................. 2 
2.2 Treatment of Right Ventricular Outflow Tract Disease ................................... 5 
2.3 Percutaneous Pulmonary Valve ................................................................................ 9 
2.4 Epidemiology and target population for PPV ..................................................... 11 
III. METHOD .............................................................................................................................. 15 
3.1 Search Method .............................................................................................................. 15 
3.2 Inclusion Criteria ......................................................................................................... 16 
3.3 Data Extraction ............................................................................................................. 18 
3.4 Statistical analysis ........................................................................................................ 18 
IV. RESULTS .............................................................................................................................. 20 
4.1 Clinical Outcome .......................................................................................................... 23 
4.2 Safety Outcome ............................................................................................................. 28 
V. DISCUSSION ....................................................................................................................... 30 
VI. LIMITATION ...................................................................................................................... 38 





Table 1. Timeline of patients with Tetralogy of Fallot in whom early complete 
repair is not feasible  ............................................................................................................ 8 
Table 2 Prevalence at birth of specified congenital heart defects in Europe ... 12 
Table 3 All-population prevalence of specified congenital heart defects in 
Korea ........................................................................................................................................ 13 
Table 4  Basic information and patient baseline characteristics of each study
 .................................................................................................................................................... 21 
Table 5  Immediate Hemodynamic Results .............................................................. 24 
Table 6  MRI follow-up data .......................................................................................... 27 
Table 7  Regurgitation Fraction ................................................................................... 27 
Table 8  Total hospital and health care costs for one-stage vs. two-stage 




Figure 1. Structure of Tetralolgy of Fallot .................................................................... 3 
Figure 2 Percutaneous Pulmonary Valve ...................................................................... 9 
Figure 3  Melody transcatheter pulmonary valve deployment using the 
EnsembleTM delivery catheter .......................................................................................... 11 
Figure 4. Diagram usage of PPVI ................................................................................... 14 
Figure 5  Flow Diagram of Study Search and Selection ....................................... 17 
Figure 6. Valvar competence during follow-up assessed on echocardiography - 






Appendix I  Meta-analysis and Systematic Review Included Studies .............. 49 
Appendix II  List of Full Reviewed Studies .............................................................. 50 
Appendix III  Summary of Included Studies............................................................ 63 




Congenital heart defects, including right ventricular outflow tract (RVOT) dysfunction, 
are severe conditions requiring multiple surgical repairs throughout a lifetime.(1) The 
typical symptom of RVOT dysfunction is cyanosis, which is blue coloration on skin 
due to lack of oxygen saturation in the tissue, and it may require interventions within 
very early in life.(1) Nowadays, with the latest medical technology, RVOT may be 
diagnosed during pregnancy with ultrasound by obtaining views of the outflow tracts.(1) 
RVOT dysfunction encompasses pulmonary valve stenosis, pulmonary valve 
incompetence, or the two combined; specific associated diagnoses are tetralogy of 
Fallot (ToF), truncus arteriosus (TA), transposition of the great arteries (TGA), and 
others.(2) Treatment mostly involves surgical repairs to the RVOT structure, and, 
depending on its severity, clinical outcomes may vary.(3)  
 
RVOT dysfunction requires surgical repair, and if it is untreated the actuarial survival 
chances decrease significantly.(4) Lifetime interventions of RVOT dysfunction results 
in increased morbidity and mortality along with high costs; therefore, there is a need to 
reduce the total number of interventions required, and especially to avoid open heart 
surgery.(5) The percutaneous pulmonary heart valve was introduced in 2000, and it has 
been used in limited countries since then.(6) The aim of percutaneous pulmonary heart 
valve implantation is to restore and maintain pulmonary valve competence without 
need of an open-chest operation. When the percutaneous pulmonary heart valve was 
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first developed by Bonhoeffer in 2000, it was a bovine jugular valve sutured inside a 
balloon expandable platinum iridium stent.(6) Several studies concluded that it 
successfully restores the pulmonary valve function and has a high success rate with 
relatively acceptable safety profile.(7)  
 
Pulmonary heart valve implantation has shown to delay the need for open-chest 
surgery, thus, could reduce the total number of interventions over lifetime according to 
various research findings.(8) However, there has not yet been research done among 
large populations to study clinical outcomes, and the quantitative result of safety and 




2.1 Right Ventricular Outflow Tract Disease 
Congenital malformation on right ventricle and pulmonary artery often cause severe 
symptomatic conditions in early life, which eventually result in the need of series of 
interventions. Symptoms of RVOT disease include blue baby syndrome, which occurs 
in babies with cyanotic heart defects caused by insufficient blood flow.(2) In most 
cases, intervention is required in early stage of life. RVOT usually encompasses 
pulmonary valve stenosis, pulmonary valve incompetence, or the two combined.(2) 
Associated diseases are ToF, TA, TGA, and double outlet right ventricle (DORV) 
diseases.(2) This section intends to provide pathophysiology and epidemiological 
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background of each associated disease.  
 
Tetralogy of Fallot  
ToF is the most commonly occurring RVOT disease, and it is characterized by four 
major anatomical abnormalities of the heart: pulmonary artery stenosis, ventricular 
septal defect, deviation of the aortic origin to the right, and right ventricular 
hypertrophy.(9) Each structural abnormality described in Figure 1.(10) ToF is also the 
most common congenital heart disease amongst live-born children, and its prevalence 
rate amongst congenital heart diseases is 9.6%.(11) As with many other congenital 
diseases, the cause of the disease is unknown; however, commonly, deletion of gen 
22q11.2 is detected in ToF patients and it is widely used as a diagnostic tool.(12)  
 




Truncus Arteriosus  
TA is a congenital heart disease with a single arterial trunk arising from ventricles by 
means of a single truncal valve. Pulmonary arteries may arise from the common trunk 
in one of several patterns, which are often used to classify subtypes of TA. Early 
classification, developed by Collett and Edwards in 1949, classifies TA into four 
different types ( I, II, III, and IV) by structural characterization of the pulmonary 
trunk.(13) TA is a relatively uncommon congenital heart disease amongst live-born 
children and its rate of occurrence is about 1.4%.(11) Pathophysiology of TA is typified 
by cyanosis and systemic ventricular volume overload, which causes a need of right 
ventricle outflow. 
 
Transposition of Great Arteries  
TGA is characterized by the transposition of the great arteries, which are the 
pulmonary artery and the aorta.(14) As the great arteries are transposed, (i.e., switched), 
there are two blood circulation systems in the body, which results in a lack of oxygen 
delivery from the lungs into the whole body. Therefore, as with other RVOT diseases, 
TGA also results in cyanotic symptoms. The Center for Disease Control and 
Prevention in Unites States estimates that each year about five out of every 10,000 
babies are born with TGA.(15)  
 
Double Outlet Right Ventricle  
DORV is a form of ventriculoarterial connection in which both of the great arteries 
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connect completely or partially to the right ventricle.(14) DORV often presents with 
other coexisting ventricular anomalies such as mitral stenosis and TGA. DORV with 
subaortic ventricular septal defect usually yields physiology similar to ToF because 
the blood from the left ventricle flows to the aorta and blood from the right ventricle 
flows to the pulmonary artery, and DROV with subpulmonic ventricular septal defect 
usually yields physiology which is similar to TGA because blood from the left 
ventricle flows to the pulmonary artery, and blood from the right ventricle flows to the 
aorta.(14) DORV accounts for about 0.7% of all congenital heart diseases of live-born 
children.(11) 
 
2.2 Treatment of Right Ventricular Outflow Tract Disease  
RVOT dysfunctions discussed above (ToF, TA, TGA, and DORV) have a common 
symptom of cyanosis in the patient’s early years, also known as blue baby syndrome. 
The symptom of cyanosis occurs due to the lack of continuity between the right 
ventricle and the pulmonary artery. Severity of symptoms may vary depending on the 
type of structure abnormality, and it typically presents with pulmonary valve stenosis, 
pulmonary valve incompetence, or the two combined. Treatment of RVOT 
dysfunction mostly involves surgical repair, and if it is untreated, the actuarial survival 
rate is approximately 75% after the first year of life, 60% by four years, 30% by ten 




Depending on the severity of the RVOT disease, a medical decision is made as to 
whether surgical repair is needed. Most often, RVOT diseases requires surgical repair, 
which is usually performed in two stages, which are repair and initial revalving.(16) 
There are different types of surgical repairs and techniques that are used to treat 
RVOT diseases, and the techniques are chosen depending on the types of dysfunction. 
Types of surgeries that are commonly performed are Rastelli, Fontan, Ross, Konno, 
Norwood, among others.  
 
Through primary surgical repair, the most common serious symptom, pulmonary 
regurgitation, which is, due to the ventricular function affecting the valve function, is 
generally managed and shows effective outcomes (17). Moreover, chronic volume 
overload of the right ventricle leads to ventricular dilatation and impairment of systolic 
and diastolic function, which in the long term leads to reduced exercise tolerance, 
arrhythmias, and an increased risk of sudden death. Therefore, after the first surgical 
repair, in later life, another repair procedure is often required to treat stenotic valved 
conduits. For stenotic valved conduit, there are several interventional procedures 
available: balloon angioplasty, percutaneous stent implant, and surgical 
implant/replacement of the RV–PA conduit. These interventional procedures reduce 
pressure gradient in RV–PA conduits, but the effect is shown to be short-lived and 
does not significantly delay the next surgical repair.(18)  
 
RV–PA conduits that are surgically inserted show effective outcomes such as low 
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perioperative mortality of 1–4% and 10-year survival of 86–95%.(19) However, since it 
is surgically implanted, there are risks involving cardiopulmonary bypass, infection, 
and bleeding, and ventricular dysfunction remains, as well as the chronic impact on 
the myocardium and brain.(20) The RV–PA conduit of freedom from replacement is 
68–95% at 5 years, and 0–59% at 10 years.(18)  
 
Therefore, the result of RV–PA conduit follow-up indicates that the need of repair or 
replacement increases greatly after 10 years of the first conduit procedure; on the other 
hand, the new currently available prosthetic conduits’ functional life expectancy is 
limited. Thus, as previously discussed, patients with RV-PA conduit would eventually 
go under a series of operations in their lifetime in order to replace degenerated conduit.   
 
Although Neyt et al. found uncertainty of timing of operation and PPVI indication in 
later life, they illustrated the timeline of ToF repair in patients for whom early 
complete repair is not feasible, as shown in Table 1.(16) As the table shows, after initial 
revalving for the replacement of conduit, PPVI may be appropriate for all, and the age 
and number of repairs in later life may vary between patients.(16) 
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Table 1. Timeline of patients with Tetralogy of Fallot in whom early complete 
repair is not feasible (16) 
 
 
Patients with congenital cardiac defects involving the right ventricle and pulmonary 
artery face multiple re-operations over a lifetime; therefore, there is a need for valve 
repair or replacement performed with minimally- or less-invasive techniques. The 
term “less invasive” implies that the patient spends less time in the operating room, 
acute care unit, and rehabilitation. “Minimally invasive” also implies less discomfort 
and less impairment of the patient’s and the caregiver’s daily activities. Early 
intervention could restore RV function.  
 
The percutaneous pulmonary valve implantation is intended to relieve conduit stenosis 
without inducing regurgitation, to restore and maintain pulmonary valve competence 
with the goal of extending the right ventricle to pulmonary artery conduit life, and 
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ultimately decrease the number of repeated surgical interventions over a patient’s 
lifetime. 
 
2.3 Percutaneous Pulmonary Valve 
Today, there are two types of marketed pulmonary heart valve – MelodyTM, Medtronic, 
and SapienTM, Edwards.(21) The Melody valve is a bovine jugular vein valve sutured 
within a platinum iridum stent and preserved in a proprietary sterilant of 
glutaraldehyde and alcohol.(21) The Sapien pulmonary transcatheter heart valve is a 
bovine pericardium valve with a radiopaque, stainless steel balloon-expandable 
support structure, and a polyethylene terephthalate fabric cuff.(21) The images of the 
two valves are shown in Figure 2.  
 






PPVI procedure is very similar to the coronary artery stenting procedure. The patients 
are usually under general anesthesia, and physicians use fluoroscopy to overlook and 
monitor the progress of transcatheter procedure. The puncture site used for 
transcatheter insert is typically the femoral vein, and angiography is used to identify 
the anatomy of RVOT along with other coronary arteries and veins. The catheter-
based delivery system is used to insert the valve, and the delivery system that is used 
for each percutaneous pulmonary valve is the NovaFlexTM delivery system for 
SapienTM and the EnsembleTM delivery system for MelodyTM. Prior to inserting the 
delivery system, the percutaneous pulmonary valve is carefully positioned at the end 
of the catheter, which has a balloon matching with the diameter of the used valve.  
 
Using fluoroscopy, physicians then position the valve at the targeted site of RVOT, 
then inflate the balloon to expand the percutaneous pulmonary valve at the target valve. 
The MelodyTM transcatheter pulmonary valve deploying using the EnsembleTM 
delivery catheter is shown in Figure 3.(22) Then, the balloon is deflated and guidewire 
is removed, leaving the new valve in place. Depending on the physician’s preference, 
sometimes additional stent is used first to provide solid surface where the valve can be 




Figure 3  Melody transcatheter pulmonary valve deployment using the 




2.4 Epidemiology and target population for PPV 
Congenital heart disease prevalence rates may vary among different demographic 
groups; therefore, in this section, epidemiology for Western and Korean PPV target 
populations will be discussed separately.  
 
Epidemiology of Western Population 
In European countries, the prevalence of congenital heart disease at birth is reported as 
0.8%, indicating that, yearly, about 58,640 children are born with a significant heart 
defect.(2) In 40% of cases, no treatment is needed, whereas in the remaining 60%, 
surgery or catheter interventions are indicated,(2) which means that about 23,500 
children receive surgery or intervention yearly. The prevalences of different congenital 
cardiac anomalies at birth are depicted in Table 2. 
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Table 2 Prevalence at birth of specified congenital heart defects in Europe 
(%) (2) 
Ventricular septal defect 42 
Atrial septal defect 9 
Aortic stenosis 8 
Pulmonary stenosis 6 
Ductus arteriosus persistens 5 
Coarctatio aortae 5 
Transposition of great arteries 5 
Atrioventricular septal defect 4 
Tetralogie of Fallot 3 





Epidemiology of Korean population 
Although Korea has an easily accessible data set provided by te Health Insurance 
Review and Assessment Service, incidence or prevalence rates for different types of 
congenital heart disease populations was impossible to calculate because Korean 
Standard statistical classification does not specify the different types of CHD. 
Therefore, as with the European population, the publication search was used to 
research epidemiology of the Korean population. Unfortunately, there was no 
published study regarding the prevalence at birth; however, there was a study 
performed on prevalence of specified congenital heart defects in Korea.(23) The 
research calculated the incidence rate and prevalence rate of all population based on 
consensus data along with their own survey. Table 2 shows the prevalence for all 
populations for specified congenital heart defects in Korea.  
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Table 3 All-population prevalence of specified congenital heart defects in 
Korea (%)  
Ventricular septal defect 34.9 
Atrial septal defect 18.8 
Patent Ductus Arteriosus 10.0 
Tetralogie of Fallot 8.4 
Pulmonary stenosis 7.0 
Coarctatio aortae 2.7 
Attrioventricular canal defect 2.1 
Ebstein’s anomaly 2.0 
Mitral valve disease 1.9 
Aortic valve disease 1.9 
Double outlet right ventricle 1.6 





Target population of PPVI 
By referencing the Medtronic MelodyTM humanitarian device submission document, 




























* Marked boxes indicate the target population of PPVI 
 
 
Using the diagram in Figure 4, assumptions concerning the target Korean population 
calculation can be made. By Congenital Heart Disease Prevalence and Investigation 
Survey performed in 2008 to 2009 in Korea, prevalences of each PPVI target disease 



































of those populations, the rates of patients who receive surgical treatments are – ToF 
83%, TA 77%, TGA 92%, and DORV 79%. Through the assumption that roughly 15% 
of RVOT repair involves the RV-PA conduit, the prevalence of each PPVI target 
disease population is 1.5% of the congenital heart disease population in Korea based 
on a 2005 census (23). In other words, 1.5% of congenital heart disease population in 
Korea could be eligible to receive benefits from PPVI; therefore, safer, more effective 





3.1 Search Method 
This study was performed as per the National Evidence-based Healthcare 
Collaborating Agency (NECA) systematic review manual published in 2010. The 
literature review was performed via two electronic databases: the United States 
National Library of Medicine (PubMed, at www.ncbi.nlm.nih.gov/pubmed/) and 
Cochrane Library (at www.thecochranelibrary.com). To eliminate the possible 
omission of searched literature, broad search terms were used, as follow: 





3.2 Inclusion Criteria 
The published journal search took place in April 2014. To align the literature search to 
the objective of this study, the following selection criteria(24) were used – studies with 
clinical data available for patients who were treated by a regulatory approved 
percutaneous pulmonary valve – MelodyTM, or SapienTM –, studies with complete 
published article, studies with human subjects only, and studies published in English. 
Furthermore, studies in the form of case reports were excluded, and if the study was 
published more than once, the published articles, which contain more complete data, 
were included. The overview of search method and selection is summarized 



































Studies identified by literature search (n=599) 
PubMed (n=591) 
Cochrane (n=8) 
Full paper review (n=108) 
Abstract reviewed, excluded 
Other subject (n=404) 
Case report (n=37) 
Non-clinical (n=37) 
Review article/Editorial letter (n=3) 
Duplicate (n=10) 
 Studies included in the analysis (n=10) 
Full paper reviewed, excluded 
Other subject (n=51) 
Case report (n=14) 
Non-clinical (n=3) 
Non-English (n=3) 
Review article/Editorial letter (n=11) 
Not full article (n=3) 
Duplicate data (n=14) 
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3.3 Data Extraction 
From eligible studies, baseline characteristics and clinical safety and efficacy 
outcomes were extracted from each study using Microsoft Word and Excel. Due to 
data characteristics, safety outcomes were not able to be included in the meta-analysis, 
while efficacy outcomes were. Commonly, immediate hemodynamic data along with 6 
months’ follow-up MRI data were mainly described in the selected articles.  
A second reviewer also independently searched, in/excluded, and extracted data. 
These data was compared to the first reviewer’s data for accuracy. If there was any 
disagreement between the two, it was resolved by discussion and agreement. 
 
3.4 Statistical analysis 
Endnote software version X7.1 (Thomson Reuters, New York, USA) was used for 
publication review, and RevMan 5.2 (Nordic Cochrane Centre, Cochrane 
Collaboration, Copenhagen, Denmark) was used for meta-analysis. The model used 
for meta-analysis was a fixed-model. Publication bias will be confirmed; funnel plots 
were constructed to inspect the symmetry visually. 
 
Related Statistical Algorithm in RevMan 
PPVI clinical outcomes are in a structure of continuous measurement of pre-procedure 
and post-procedure groups. Therefore, the following data formation was used for the 
analysis:(25) 
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 Group size Mean response Standard deviation 
Pre-procedure n1i m1i sd1i 
Post-procedure n2i m2i sd2i 
 
The mean difference is defined as MDi = m1i - m2i, and standard error is defined as  
(25) 
In order to pool the intervention effect – continuous PPVI outcomes –, which are all 
mean differences along with standardized mean differences, RevMan uses the inverse-
variance method. The intervention effect is denoted as , whereas the individual 
effect sizes are weighted according to the reciprocal of their variance: 
(25) 
Heterogeneity of included studies was tested by using the method similar to the 
Mantel-Haenzel method. The k represents the number of included studies in the 
analysis, so k-1 degrees of freedom chi-square distribution was used to test the null 







The number of searched studies was 599 by using electronic database – PubMed and 
Cochrane. Abstract review was performed for all searched studies. Among those 
excluded were 404 non related studies, 37 case report studies, 37 non-clinical studies, 
three review articles and editorial letters were excluded, and 10 duplicate studies. A 
full review was performed on 108 studies. Among the 108 fully reviewed studies, 51 
non-related studies, 14 case report studies, three non-clinical studies, three non-
English studies, 11 review articles and editorial letters, three non-full studies, and 14 
studies with duplicate data were excluded.  
 
Thus, ten studies were finally included in this study. The list of included studies is 
given in Appendix I. In addition, the list of fully reviewed studies along with each 
exclusion criteria is described in detail in the Appendix II. The total number of 
included patients is 697 patients and their procedure period was from 2005 to 2012. In 
all included studies, PPVI was performed for those regulatory approval indications, 
such as patients with regurgitant prosthetic RVOT conduits with clinical indications 
for invasive or surgical intervention, and for patients with stenotic prosthetic RVOT 
conduits where the risk of worsening regurgitation is a relative contraindication to 
balloon dilation or stenting.(26, 27) Each included study’s summary, including study 
design, method, and outcome, is described in Appendix III. 
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Although for some studies lacked the information on indication and contraindication 
of PPVI, for those had the information, the common indication and contraindications 
for PPVI were as follow:  age >5 years, weight >20kg, conduit right ventricular 
outflow tract 16–18mm or ≤22mm, severe pulmonary regurgitation, progredient RV 
dilation and reduced RV function, symptomatic patients with declining exercise 
tolerance, increased RV pressure, a combination of stenosis and regurgitation with RV 
dysfunction and dilation, and supraventricular or ventricular rhythm disturbances. In 
addition, the common contraindications of PPVI were active infection, abnormality of 
coronary artery, and pregnancy.  
 
 
Table 4  Basic information and patient baseline characteristics 
of each study 











Tetralogy of Fallot (n=4) 
Pulmonary atresia with VSD (n=3) 
Truncus arteriosus (n=4) 
Double outlet right ventricle (n=2) 









Tetralogy of Fallot (n=27) 
Truncus arteriosus (n=5) 
Aortic valve disease (n=9) 











– Jul 2010 
Tetralogy of Fallot/pulmonary atresia 
(n=61) 
TAC (n=14) 
transposition of the great arteries (n=9) 










Tetralogy of Fallott (n=77)  
Truncus arteriosus (n=7) 
Pulmonary stenosis (n=7)  
Dextro-transposition of the great arteris 
(n=4)  
Aortic stenosis (n=4)  
Double-outlet right ventricle (n=1)  









Tetralogy of Fallott (n=11) 




Double outlet right ventricle (n=2) 









Tetralogy of Fallot (n=16) 
Ross procedure (n=11) 












Tetralogy of Fallot (n=94) 
Double outlet RV (n=9) 
TGA, VSD, PS (n=14) 
Ross procedure (n=12) 









Tetralogy of Fallot (n=65) (46%) 
Aortic valve disease after Ross operation 
(n=28) 
Transposition of the great arteries (n=15) 
Truncus arteriosus (n=14) 
Double-outlet right ventricle (n=8) 










Tetralogy of Fallot (n=7) 
Aortic valve disease (n=7) 
Transposition of great arteries (n=4) 
Double outlet right ventricle (n=3) 
Trucus arteriosus (n=2) 
Pulmonary atresia (n=2) 












Pulmonary Atresia with Ventricular 
Seaptal Defect (n=9) 
Tetralogy of Fallot (n=7) 
Paroxysmal Atrial Tachycardia (n=5) 
Double outlet right ventricle(n=2) 
Aortic insufficiency (n=2) 
Transposition of great arteries with 





4.1 Clinical Outcome 
 
Immediate Hemodynamic Results 
Most studies included outcomes of immediate hemodynamic result, and in total there 
were 10 studies included.(28, 30-35, 37-39) However, due to varying techniques and units of 
measurement, only those with three or more study data with the same measurement 
were pooled for meta-analysis, shown in Table 2.  
 
After percutaneous pulmonary valve implantation, ratio of RVP to aortic pressure was 
significantly decreased (mean difference: 27.86%, 95% CI: 24.90, 30.82). RV systolic 
pressure was significantly decreased (mean difference: 20.03mmHg, 95% CI: 17.95, 
12.11). RV diastolic pressure was decreased (mean difference: 1.69mmHg, 95% CI: 
0.94, 2.26). PA systolic pressure was increased (mean difference: -2.61mmHg, 95% 
CI: -4.35, -0.87). PA diastolic pressure was increased (mean difference: -4.37mmHg, 
95% CI: -5.25, -3.49). RV-PA gradient was reduced (mean difference: 18.96, 95% CI: 
15.94, 21.99). Aortic systolic pressure was increased (mean difference: -10.51, 95% 
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CI: -12.89, -8.14).  
 
Of these immediate hemodynamic results, significant heterogeneity was found in 
mean differences of ratios of RVP to aortic pressure, RV systolic pressure, and aortic 
systolic pressure. The analysis was repeated with a random-effect model, but it 
showed similar heterogeneity. To evaluate study publication, bias funnel plots were 
constructed. Due to of the small number of included studies k, and the fact that all 
included studies are not controlled studies, there was limitation to measure the 
publication bias. By funnel plot evaluation, it was determined that all tests except ratio 
of RVP to aortic pressure and RV diastolic pressure are to be 2-sided, meaning there is 
possibility of publication bias present on RVP to aortic pressure and RV diastolic 




Table 5  Immediate Hemodynamic Results 
Ratio of RVP to aortic pressure 
RV systolic pressure 
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RV diastolic pressure 
PA systolic pressure 
PA Diastolic Pressure 
RV-PA gradient 
26 
Aortic Systolic Pressure 
 
 
Mid-term Magnetic Resonance Imaging Results 
Out of the 10 studies, mid-term magnetic resonance imaging (MRI) data was available 
in four studies.(29, 33, 35, 37) Due to different unit and test used in these four, only 6 
months’ data for End-diastolic RV volume and RV ejection fraction were able to be 
pooled, as shown in Table 6.  
End-diastolic RV volume was significantly reduced (mean difference: 26.92, 95% CI: 
16.06, 37.77, p: <0.00001). There was no significant change in RV ejection fraction 
(mean difference: -1.57, 95% CI: -4.73, 1.60, p: 0.33). There was no shown 
heterogeneity on these two MRI outcomes. In addition, there was possible publication 
bias on end-diastolic RV volume, as shown in the funnel plot in Table 6.  
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Table 6  MRI follow-up data 
End-diastolic RV volume 




Out of the 10 studies, three(29, 33, 35) had data on regurgitation fraction. The data was 
pooled, and Table 7 shows its result. After PPVI, regurgitation fraction was decreased 
significantly (mean difference: 24.13, 95%CI: 21.64, 26.61, p: <0.00001).  
 






4.2 Safety Outcome 
 
Death. All the studies show a fairly short follow-up period, which led the mortality 
rate to be low. There were few death events described in 10 studies, which were 
reported in three studies.(29, 31, 34) There were three early deaths that occurred due to, 
respectively, cardiogenic shock, multiorgan failure, and complicated medical history 
which led to complicated procedure and misplacement of valve.(29, 34) After 6 months, 
there were three deaths due to respiratory insufficiency, severe liver disease, and 
progressive heart failure, respectively.(29) At 8 months, there was one sudden death due 
to arrhythmia. At 35 months, there was one sudden death due to arrhythmia.(34) In 
addition, with an unknown period, there were two deaths due to postoperative sepsis 
and hypercarbic respiratory failure.(31)  
 
Freedom from reintervention and reoperation. Freedom from reintervention and 
reoperation was reported in 4 studies. (28, 30, 34, 37) Asoh describes freedom from 
reintervention as 13/14 at 1 year, and 12/14 at 2 years. (28) Eicken describes freedom 
from reintervention as 97±2% at 1 year, and 92±5% at 2 years. (30) Lurz describes 
freedom from reoperation as 93±2 at 10 month, 86±3 at 30 months, 84±4 at 50 
months, and 70±13 at 70 months. (34) Vezmar describes freedom from reoperation as 
91% at 1 year, 83% at 2 years, and 83% at 3 years. (37) Vezmar also describes freedom 
from reintervention as 91% at 1 year, 80% at 2 years, and 80% at 3 years.(37) 
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Freedom from valve failure. Freedom from valve failure was reported in one 
study.(29) Butera describes freedom from valve failure as 81.4 ± 9% at 1 year. 
 
Procedural complication  Procedural complications occurred in eight studies as 
follows: six homograft rupture,(34, 35) five major and minor bleeding,(29, 34) three implant 
failure,(31-33) three vascular surgery requirement,(29) two embolization,(29, 33) two 
guidewire induced perforation,(35) two stent dislodge,(31, 32) two damage to tricuspid 
valve,(34) two balloon rupture,(31, 33) two device instability,(34) one femoral artery 
pseudoneurysm,(28) one ventricular fibrillation,(29) one contrast media leakage,(29) one 
transjugular access necessary,(31, 32) one Intermittent atrial flutter,(31) one pulmonary 
hemorrhage,(33) one ventricular fibrillation,(33) one THV mitigation,(33) one 
Compression of left main artery,(34) one Obstruction,(34) one coronary artery 
dissection,(35) one tachycardia,(35) one hypercarbia,(35) one femoral vein thrombosis,(35) 
one balloon angioplasty,(35) one recurrent stenosis,(37) and one conduit stenosis.(37) 
 
Other complications. Other than procedural complications, there were some 
complications found during each studies’ follow-up visits. Ten events of endocarditis 
were reported in four studies.(29-31, 34) 39 stent fractures were reported in four studies.(29-
31, 35) There was one severe compression of left coronary artery,(30) one intermittent 
atrial flutter,(33) one hemolysis,(34) one pulmonary hypertension,(35) one tricuspid 





Effectiveness of Percutaneous Pulmonary Valve Implantation 
Before the present paper, there had been several published systematic review studies 
on PPVI(40, 41) but no meta-analyzed data available. Although each outcome were 
pooled from limited number of studies, analyzed data shown in Table 2 and 3 shows 
significant improvement on immediate hemodynamic and well-maintained mid-term 
MRI outcomes. These data show statistically significant differences from pre-
implantation and post-implantation of percutaneous pulmonary valves.  
 
However, it remains controversial as to whether this value is comparable to the 
previous therapy – surgical repair of pulmonary valve. Therefore, the effectiveness of 
surgical pulmonary valve replacement was searched for reference. There was a meta-
analysis study done on surgical pulmonary valve replacement after operative repair of 
ToF.(42) Although this study only included papers with the patients who had undergone 
surgical repair of ToF, it pooled data on indexed right ventricle end diastolic volume 
(mean difference: -63, 95% CI: -72, -55) , RV ejection fraction (mean difference 1, 95% 
CI: -1, 3), and pulmonary regurgitant fraction (mean difference: -38, 95% CI: -41, -
35).(42) Similar to our previous pooled data shown in Table 2 and 3, apart from RV 
ejection fraction data, right ventricle end diastolic volume and pulmonary regurgitant 
fraction were reduced significantly. Although quantification of change is different 
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between PPVI and surgical repair, data comparison between surgical repair and PPVI 
would not be possible due to statistical limitations. 
 
Rate of regurgitation is one of the greatest tools to measure the effectiveness of PPVI, 
because it is the most important indication for the use of PPV. Among included studies 
in this paper, there were three studies with valve regurgitation outcomes. Asoh reports 
valve regurgitation as absent or mild in 100% of cases at 24 h.(28) Butera and Lurz 
describes that valve regurgitation was absent or mild in 90% of cases at 6 months.(29) 
(34) Lurz reports that valve regurgitation was absent or trivial in 80% of cases at 36 
months, as shown in Figure 6.(34)  
 





Safety of Percutaneous Pulmonary Valve Implantation 
The most common complication found in the follow-up visits was stent fracture. 
Among the included studies, four studies reported 39 cases of stent fracture.(29-31, 35) 
Stent fractures are commonly treated with repeated balloon dilatation, stent 
implantation, or operation. Requirement of another procedure or surgery makes this 
complication one of the most serious and dangerous. Nordmeyer performed a study on 
123 patients who had undergone PPVI,(43) and he reported that 21.1% patients 
developed stent fracture 0–843 days after PPVI. His study on multivariate analysis of 
stent fracture risk factors concludes that the risk factors are concluded outflow tract 
type, calcification along RVOT, and recoil of PPV.(43) The second most common 
complication was endocarditis, which was reported among four studies.(29-31, 34) It is 
also a dangerous complication, so aseptic environment is important as well as treating 
patients with appropriate intravenous antibiotics.  
 
The number of reported death events is low due to the short follow-up period. Among 
10 included studies only four studies had described event of death, which summed to 
be 12 events. There were three early deaths due to cardiogenic shock, multi-organ 
failure, and complicated medical history, respectively, which led complicated 
procedure and misplacement of valve.(29, 34) After 6 months, there were three deaths 
due to respiratory insufficiency, severe liver disease, and progressive heart failure.(29) 
At 8 months, there was one sudden death due to arrhythmia. At 35 months,(34), there 
was one sudden death due to arrhythmia.(34) Also, with an unknown period, there were 
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two deaths due to postoperative sepsis, and hypercarbic respiratory failure, 
respectively (31). The relationship of these events to medical device, PPV, or procedure, 
PPVI, is not clearly reported in the studies.  
 
Freedom from reintervention and reoperation is one of the great tools to measure the 
efficacy and safety of PPVI. There were four studies (28, 30, 34, 37) that analyzed freedom 
from reintervention and reoperation. As shown in the result session of this paper, all 
the studies consistently show fairly effective outcomes, and it also shows that the rate 
slowly decreases with time. Some studies performed on surgical pulmonary valve 
replacement describe that freedom from PV reintervention is 94% at 5 years, as shown 
in figure 7, which might seemed to be a better result than PPVI. However, statistical 
comparison between the two therapies is not possible because due to statistical 
limitations – no randomized trial, no controlled trial, and included population between 
the two studies are different.  
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Figure 7  Freedom from Reintervention 
A. Freedom from reintervention for patients eligible for percutaneous 
intervention who underwent surgical pulmonary valve replacement (44) 
 
B. Freedom from reoperation or reintervention after percutaneous pulmonary 




Cost Effectiveness of Percutaneous Pulmonary Valve Implantation 
Although the included studies do not include the data for cost effectiveness analysis, 
an additional study search was performed to consider cost effectiveness of PPVI.  
 
Cost of Surgical Repair. Prior to discussing the cost effectiveness of PPVI, cost of 
pulmonary valve surgical repair is to be discussed. While there is a limited number of 
studies performed on the cost of surgery, although the study performed by Ungerleider 
only included patients who underwent surgical repair of ToF, it describes the cost that 
is associated with its surgical repair amongst infants.(45) This study included direct and 
indirect cost of those who underwent surgical repair of ToF in the United States 
between 1993 and 1995. The study compared the cost between one-stage repair and 
two-stage repair of ToF in infants who are younger than 1 year of age, as shown in 
Table 5. However, his study did not include the cost of care that occurs later in life, 
such as outpatient visits, cardiac cauterization, and series of echocardiography. The 
costs reflected here are for a single episode of care that will be repeated several times 
during the patient’s lifetime.(45) 
 
Table 8  Total hospital and health care costs for one-stage vs. two-stage repair of 









14.5  11.2 days 
43  30.8 days (p=0.003 compared to 





$32,541  $15,968 
$79,795  $40,625 (p=0.001) 
compared to the group with primary 
repair  for the complete repair 
 
 
Cost of PPVI – United Kingdom. The study performed in the UK by Raikou 
compared the analyzed cost of PPVI with the cost of surgical valve replacement in 
RVOT dysfunction patients.(46) The used model for analysis is a cohort simulation 
model in the UK, and the mean cost for surgical procedure was £11,610.(46) This cost 
was mainly attributable to the operative duration time, intensive care, and hospital stay. 
PPVI was associated with a small increase in treatment management costs of 25 years, 
but the study was an indication of long-term cost, and did not consider short term cost 
effectiveness.(46) Based on the assumptions stated above and using a Markov 
simulation over 25 years, the model resulted in an estimate of mean cost per patient of 
£5,791 in the absence of PPVI, and in an estimate of mean cost per patient of £8,734 
in the presence of PPVI.(46)  
 
Cost of PPVI – United States. Between 2010 and 2011 at a single center in the US, a 
prospective Markov simulation modeling out to 10 years for 17 patients who received 
PPVI or surgically placed pulmonary valve.(47) The study compared the cost-
effectiveness of PPVI to the standard surgical repair, and the used data included actual 
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procedural and in-hospital charges, estimation for 5 and 10 year future modeling with 
appropriate sensitivity analysis. 10-year simulation resulted in surgery costs of $150,437 
compared to $128,129 for PPVI.(47) Furthermore, the study concluded that it would need 
to have very high failure rate to lose its advantage but for now PPVI demonstrated a 6% 
per year valve failure requiring reintervention. (47) Overall, PPVI was found to have 
lower initial procedural costs, less time lost from work, and lower length of stay 
compared to surgery.(47)  
 
Benefits of Percutaneous Pulmonary Valve Implantation 
Even though there were some procedural complications reported in the included 
studies, such as homograft rupture,(34, 35) major and minor bleeding,(29, 34) implant 
failure,(31-33)  and vascular surgery requirement,(29) its utmost benefit of percutaneous 
pulmonary valve implantation compared to surgical valve implantation is its reduced 
invasiveness. Advantages of transcatheter procedure over surgery are well described 
through many studies. Lee et al. report the following advantages: less invasive, low 
risk of bleeding and infection, and low costs compared with surgical procedure.(40) The 
most important advantage is providing means of limiting the duration and severity of 
RV volume and/or pressure overload without increasing the lifetime number of open 






Lack of Included Study Number    
As previously mentioned, there are several limitations to this study. First, the number 
of included studies is very limited. The reason for the lack of studies is that the 
characteristics of RVOT dysfunction have low incidence and prevalence rates amongst 
live born babies. In addition, PPVI was introduced fairly recently, in 2000, and is not 
yet marketed around the world, but only to very limited countries such as the U.S. and 
in Europe. 
 
No Controlled Study to Encounter PPVI Effectiveness 
Second, there is no randomized or controlled study available to confirm the 
effectiveness of PPVI over the previous method (surgical repair). It may be 
questionable as to how it could be possible considering the fact that PPVI is already a 
marketed and approved product in many counties. This is due to PPVI’s classification, 
which lead it to be regulated differently. As previously discussed, the incidence rate of 
PPVI target population is relatively low, which leads it to be classified as a rare 
disease. Many countries around the world regulate the rare disease differently, and 
demonstration of the scientific efficacy of the product may not be necessary to gain the 
product approval, and the below session will address each of the regulations that waive 
the scientific efficacy requirement of the product submission for the approval.  
39 
 
United States. U.S. Food and Drug Administration (FDA) states the following in the 
21 CFR 814.3 – “humanitarian use device” (HUD) means a medical device intended 
to benefit patients in the treatment or diagnosis of a disease or condition that affects or 
is manifested in fewer than 4,000 individuals in the United States per year.   
 
In order to be categorized as a HUD, a humanitarian device exemption (HDE) 
application needs to be submitted and be approved by FDA. CFR Sections 514 and 
515 also illustrate the approval application steps for HUD. The HDE submission 
document is similar to the premarket approval application, which includes technical, 
non-clinical laboratory study, and clinical investigation. The only difference between 
HUD approval requirement and regular pre-market approval requirement is that under 
the investigational device exemption clinical investigation information on 
scientifically valid clinical investigation on medical device effectiveness is waived. 
However, even though the effectiveness information is not required for HUD approval, 
ample information on risk and benefit of the device usage and the demonstration of no 
comparable devices are available. Referencing from the MelodyTM HUD submission 
document, which was the first FDA submission for percutaneous pulmonary valve, 
scientific assumption of U.S. number of PPVI target population number is 1070 per 
year and it was, thus, categorized as a HUD. 
 
Europe. The European Union regulates medicines for rare disease differently by 
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orphan designation. European Medicine Agency’s Committee for Medicinal Products 
(COMP) for human use designates orphan medicine if the following criteria are met: it 
must be for life-threatening or chronically debilitating conditions; prevalence of the 
condition must not be more than 5 in 10,000 or generate sufficient returns to justify the 
investment; and no satisfactory method of diagnosis, prevention, or treatment of the 
condition concerned can be authorized.(48) 
 
The application needs to be completed as Directive 2001/83/EC states by including the 
following rationales in each section: quality, biologicals, non-clinical, clinical efficacy 
and safety, and multidisciplinarity. For specific products, the application requirement 
can be consulted guided by COMP, and orphan devices offer benefits to the company 
by incentives such as reduced fees and protection from competition once the product is 
placed on the market. The European Medicines Agency and US Food and Drug 
Agency work closely together to minimize the approval timeline and expedite the 
process by allowing applications for orphan-medicine designations to be submitted in 
parallel. Recently, Pharmaceuticals and Medical Devices Agency (PMDA) also began 
this cooperation in 2013. 
 
South Korea. Korea has similar regulations as U.S. Devices to treat rare disease 
regulated by the “rare medical device designation policy.” In order for the medical 
device to be categorized and approved as rare medical devices, the following criteria 
needs to be fulfilled: an incidence population of 20,000 or less, indication population 
41 
is not enough to show clinical effectiveness, no other alternative product available. 
 
Effect of Learning Curve 
Third, the effect of learning curve on safety and efficacy outcomes of PPVI was not 
encountered. As per research done by Lurz in 2008, safety and efficacy outcomes are 
greatly affected by the operator’s learning curve, and it was proven that there was 
statistically significance.(34) However, in most published articles that were included in 
this study, there was a limited amount of information on physicians’ experience of 
PPVI. Therefore, considering physicians’ experience in this study was not possible. 
Moreover, timing of operation of initial surgery as well as PPVI procedure and 
baseline characteristics of patient may greatly affect the safety and efficacy outcomes 
according to the study performed by Oosterhof(49); however, this factor could also not 





Meta-analysis and systematic review of 10 published articles since 2005 shows 
clinically significant improvement in safety and efficacy percutaneous pulmonary 
valve implantation. However, to conclude more definitive outcome, more studies are 
required for reliable evidence of efficacy for large populations and long-term analysis, 
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Appendix III  Summary of Included Studies 
 
Asoh 2010  
Method Retrospective study (U.S) 
Participants 14 children undergoing PPVI into a bioprosthetic pulmonary valve 
Inclusion criteria : all children who underwent PPVI from October 
2005 to February 2008 
Exclusion criteria : received a valve implantation in other than a 
bioprosthetic valve 
Patient Characteristics 
Gender M:7 F:7 
Primary diagnosis Tetralogy of Fallot (n=4) 
Pulmonary atresia with VSD (n=3) 
Truncus arteriosus (n=4) 
Double outlet right ventricle (n=2) 
RVOT morphology Hancock conduit (n=11) 
Native outflow tract with valve 
implantation (n=3) 




Time from prosthetic 
valve implantation to 
PPVI 
10.4±4.0 years 
Age (Range) 15.4±2.0 (13.0-19.0) years 
Body Weight (Range) 56.8±7.5 (44.2-71.7) kg 
Indication  Predominant stenosis (n=2) 
Predominant regurgitation (n=2) 
Combined lesion (n=10) 
64 
Clinical symptoms Exercise intolerance (n=5) 
Dyspnea (n=2) 
Chest pain (n=1) 
Arrhythmia (n=1) 
Asymptomatic (n=5) 
Intervention MelodyTM transcatheter pulmonary valve stent mounted on 
EnsembleTM delivery system 
Outcome & 
Result 
Immediate Hemodynamic results 




























Angiography in the 




Procedural Complications & Hospital stay 
One child (7.1%) had femoral artery pseudoaneurysm – hospital stay: 
3 days 
Others discharged within 2 days 
Immediate echocardiographic findings (within 24 hrs) 
 Before After p value 













Grade of PR 3.6±0.8  0.6±0.9 P<0.001
Time related changes in Echocardiographic data 
At latest follow-up (mean 12.9±9.8 months) 
Mean RVP : 52.1±14.4mmHg 
RVOT: 28.9±12.7 mmHg 
RVP/AoP ratio : 48±15% 
Increase in aortic valve annulus diameters (p<0.001) 
Increase in LV end-diastolic dimensions (p=0.01) 
No change in the degree of PR compared to immediately after PPVI 
Freedom from re-intervention  
3 months: 100±0 % 
12 months: 91.7±7.8 % 
25 months: 81.5±12.0 % 
32 months: 81.5±12.0 % 
Notes  
Cochrane’s Risk of Bias 







No Non randomized/Retrospective 
study 




Butera 2012  
Method Prospective, observational, multicenter registry (Italia) 
Participants October 2007 to October 2010, 63 patients were included in the 
registry 
Inclusion criteria: age >5 years, weight >30kg, original conduit 
diameter ≥16mm and/or RVOT and pulmonary artery diameter 
<22mm, patients in NYHA class II-III-IV with a Doppler mean 
gradient >35mmHg and/or moderate pulmonary valve regurgitation, 
patients in >40mmHg and/or severe pulmonary valve regurgitation 
Exclusion criteria: active endocarditis, infection or sepsis, pregnancy, 




Age (yrs) 24 (11-65) 
Weight (kg) 60 (30-140) 
Sex (F/M) 31/32 
NYHA class I: 15, II: 25, III: 16, IV: 7 
Original Diagnosis Tetralogy of Fallot: 27, Trucus 
arteriosus: 5, Aortic valve disease 
(Ross Procedure): 9, Transposition of 
the great arteries: 7, Other: 15 
RVOT conduit type Homograft : 33, Biological valved 
conduits: 28, Other: 5 
Primary indications for 
implantation  
Stenosis: 21 (33%), Regurgitation: 12 
(19%), Mixed: 30 (48%) 







Intervention Melody valve and Ensemble delivery system 
Outcome & 
Result 
Femoral approach was used in 59/63 patients, jugular approach was 
used in 4/63 patients 
Valve was delivered in 61 patients (97%). One aborted because of left 
coronary artery compression during balloon testing, other one aborted 
because of low gradient and mild pulmonary regurgitation. 




RV systolic pressure, 
mmHg Median (range) 
80 (70-100) 20 (10-30) <0.001 
Peak-to-peak systolic 
RV-PA gradient, mmHg 
Median (range) 
45 (35-75) 10 (0-30) <0.001 
RV/Ao pressure ratio 
Median (range) 
0.8 (0.6-1) 0.4 (0.15-0.7) <0.001 
Change of pulmonary regurgitation grade 
Grade  Pre-procedure Post-procedure Latest follow-
up 
0 0 30 29 
1 0 10 9 
2 5 1 1 
3 21 1 1 
4 16 0 0 
Procedural Complications 
Complications occurred in nine patients (14%) 
68 
Major complication occurred in two patients (pulmonary valve 
embolized, ventricular fibrillation) 
Other complications in seven patients (ventricular fibrillation) 
Post procedural course 
Hospital stay: 8 patients needed ICU stay for medium time of one day 
(range 1-45 days). Median hospital stay was five days (range 3-45 
days) 
Mortality: One patient experienced early death 
Follow-up data 
Median 30 months (range 12-48 months) 
One external electrical cardioversion due to atrial fibrillation, three 
deaths, two bacterial endocarditis needing surgical explantation, and 
two significant stent fractures needing second valve implantation 
Freedom from valve failure and right ventricular outflow tract 
reintervention at latest follow-up was 81.4±9%. 
Magnetic Imaging Resonance Data 































End systolic LV 
volume 





57±8 (44-71) 58±8 (41-70) NS 
Regurgitant 
fraction (%) 
35±10 (5-50) 8±7 (0-15) 0.001 
Notes  
Cochrane’s Risk of Bias 







No Non randomized/Registry  




 Multi-site, consecutive enrollment 
Participants December 2006 to July 2010, 102 consecutive patients who were 
scheduled for PPVII at the German Heart Centres Munich and Berlin 
Age >5 years, weight >20kg 
Conduit right ventricular outflow tract > (16) 18mm ≤22mm 
Severe pulmonary regurgitation, progredient RV dilation and 
reduced RV function 
Symptomatic patients with declining exercise tolerance 
Increased RV pressure 
A combination of stenosis and regurgitation with RV dysfunction 
and dilation 
70 
Supraventricular or ventricular rhythm disturbances 
Patient Characteristics 
Gender Female, 40; male, 62 
Diagnosis TOF/PA, 61; TAC, 14; TGA, 9; AoS, 8; other, 
10 
Conduit RV-PA Homograft, 79; Contegra, 6; non-valved, 6; 
Hancock, 3 
Shelhigh, 1; matrix, 1; Carpentier-Edwards, 1; 
none, 5 
Pre-stenting Yes, 97; no, 5 
Age at PPVI 
(years) 
21.5 (16.2-30.1) 
Weight (kg) 63.0 (54.2-75.9) 
Intervention Melody, Medtronic, Inc., Minneapolis, MN, USA 
Outcome Immediate results of Percutaneous Pulmonary valve Implantation 
The systolic gradient between the right ventricle and the pulmonary 
artery was reduced from a median value of 37 mmHg (29-46mmHg) 
to 14 mmHg (9-17mmHg, p<0.00001) 
The ratio between systolic right ventricular and aortic pressure was 
decreased from a median value of 62% (53-76%) to 36% (30-42%, 
p<0.001)  
In patients with nearly normal RV pressure, pulmonary regurgitation 
was the prevailing cardiac lesion. 
Pulmonary regurgitation assessed by MRI was reduced from a 
median value of 16% (5-26%) to 1%(0-2%, p<0.001) 
The right ventricular end-diastolic volume index assessed by MRI 
decreased from a median value of 106 mL/m2 (93-133 mL/m) to 
median value of 90mL/m2 (71-108 mL/m2, p<0.001) before hospital 
discharge 
71 
The patients were discharged home at median 2 days after the 
intervention. 
Notes  
Cochrane’s Risk of Bias 




No Described as nonrandomized 
Allocation 
concealment 
Unclear Information not available 




Method Multi-center, retrospective study 
Participants Patients who underwent TPVI of a Melody to BPV in the pulmonary 
position at 8 centers in the United States between April 2007 and 
January 2010 
Demographic and Diagnostic Data 
Age, y 26 (3-63) 
Weight, kg 68 (16-199) 
Underlying anatomy Tetralogy of Fallot 74%, Truncus arteriosus 
7%, Pulmonary stenosis 7%, 
Dextrotransposition of the great arteries 




Carpetier-Edwards Perimount 37%, 
Medtronic Hancock Conduit 37%, 
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Medtronic Mosaic 7%, Medtronic Hancock 
2 7%, Medtronic Freestyle 4%, Sorin 
Mitroflow 3%, Carpentier-Edwards aortic 
porcine 3%, St Jude Biocor 2%, Ionescu-







Intervention Melody valve implant within a surgically placed BPV 
Outcome The peak RV-PA gradient decreased from 38.7±16.3 to 10.9±6.7 
mmHg(p<0.001) 
RV systolic and diastolic pressure fell from 71.6±21.7 to 
46.7±15.9 mmHg and from 11±4.6 to 10.4±3.7mmHg, 
respectively (both p<0.001) 
The mean right artrial pressure decreased from 11.4±4.4 to 
10.4±3.7 mmHg (p=0.006) 
The systolic and diastolic PA pressures increased from 32.7±14.1 to 
36.2±15.7 mmHg (p=0.02) and from 12.8±5.1 to 17.2±7.1 mmHg 
(p<0.001) 
Freedom from reintervention on the Medlody vavle, which was 
identical to freedom from explant, was 97.2±2% at 1 year and 
92±5% at 2 years 
Freedom from a diagnosis of Melody valve stent fracture was 
98±2% at 1 year and 95±3% at 2 years 
Pulmonary regurgitation: None 79%, Trivial or Mild 21%, Moderate 
or Severe 0% 
73 
Notes  
Cochrane’s Risk of Bias 




No Described as nonrandomized 
Allocation 
concealment 
Unclear Information not available 




Method Prospective (not specified any further) 
Participants 22 patients who has underlying primary diagnosis 
Patient characteristics 
Gender Female 9, Male 13 
Age  21.7 (range 6-83) 
Weight  56.5kg (range 20-91) 
Primary 
diagnosis 
Tetralogy of fallot 11 




Double outlet right ventricle 2 
Absent pulmonary valve 1 
RVOT anatomy 
prior to valve 
implantation 








Pulmonary stenosis 2 
Pulmonary regurgitation 11 
Combined PS/PI 9 
Intervention PPVI using the Edwards SAPIENTM 
Outcome Invasive hemodynamic data 
 Pre Post p 
RV-pressure systolic 61.2(±23.1) 41.2(±8.6) <0.05 
PA-pressure systolic 25.8(±8.6) 33.9(±9.2) <0.05 
PA-pressure diastolic 6.0 (±5.6) 14.6 (±4.3) <0.05 
Systolic gradient 37.3 (±23.2) 6.9 (±5.3) <0.05 
Pulmonary 
regurgitation 
   
None/trivial 2 21  
Mild 1 0  
Moderate 9 0  
Severe 10 0  
Echocardiographic data 
RV-pressure systolic 69.7(±25.6) 40.9(±10.3) <0.05 
Flow velocity RVOT 3.7(±1.0) 2.3(±0.5) <0.05 
Cochrane’s Risk of Bias 




No Described as nonrandomized 
Allocation 
concealment 
Unclear Information not available 
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Method Early phase I trial, international, multicenter, 1-arm, clinical trial 
Participants Apr 2008 to May 2010, 36 patients from 4 centers were enrolled. 
Demographics 
Age 30. 3±15.1 
Weight 73.4±22.9 
Gender Male 24, Female 12 
Diagnosis Tetralogy of Fallot 16 
Ross procedure 11 
Transposition of the great arteries 1 
Other 8 






Homograft 29, Other 7 
Primary indication Stenosis 15, regurgitation 19, mixed 2 
RVOT pre-stenting Stent placed at time of procedure 24 
Stent placed before day of procedure 12 
Intervention Edwards SAPIEN in the pulmonary position 
Outcome Comparative TTE, MRI, CPET data 
 Pre Post (6 
months) 
P 
Transthoracic echo    
Conduit peak gradient 41.9±26.2 19.1±13.3 <0.001 
76 
Conduit mean gradient 24.0±15.0 12.0±8.8 <0.001 
Estimated RV pressure 67.3±20.6 49.3±11.1 0.005 
Magnetic resonance 
imaging 
   
Pulmonary regurgitant 
fraction 
28.64±18.0 3.47±5.40 <0.001 
RV end-diastolic 
volume 
130.9±62.6 86.9±19.6 0.02 
Cardiopulmonary 
exercise testing 
   
Peak Vo2 22.1±9.4 23.1±8.0 0.09 
RQ at peak exercise 0.9±0.1 0.9±0.2 0.23 
Cochrane’s Risk of Bias 




No Described as nonrandomized 
Allocation 
concealment 
Unclear Information not available 




Method Prospective study (no other information provided) 
Participants Sep 2000 to Feb 2007, 155 patients enrolled 
Inclusion criteria 
RV systolic pressure >2/3 of systemic plus symptoms, or 
77 
RV systolic pressures >3/4 of systemic in absence of symptoms, 
and/or 
Moderate/severe PR and 1 of following criteria: 
Symptoms , sever RV dysfunction, severe RV dilation, impaired 
exercise capacity  
RVOT dimensions < 22 X 22 mm 
RVOT dimensions > 14 X 14 mm 
Characteristics 
Age 21.2 (7-17) 
Diagnosis Tetralogy of fallot 60.6% 
Double-outlet RV 5.8% 
TGA, VSD, PS 9% 
Ross procedure 7.7% 





Other conduit type 4.5% 
Patch-extended RVOT 1.3% 
Native outflow tract 3.2% 
Other 2.6% 
NYHA I 11%, II 52.9%, III 29%, IV 7.1% 
Intervention MelodyTM 
Outcome Pressure at Catheterization 
Parameter Pre Post P 
RV systolic pressure 63±18 45±13 <0.001 
RV end-diastolic pressure 12±4 10±5 <0.001 
PA systolic pressure 27±11 29±12 0.056 
PA diastolic pressure 10±4 14±9 <0.001 
78 
RV-PA gradient 37±20 17±10 <0.001 
Aortic systolic pressure 94±15 101±16 <0.001 
Aortic diastolic pressure 54±10 58±10 <0.001 
RV-to-systemic pressure 69±19 45±14 <0.001 
Cochrane’s Risk of Bias 




No Described as nonrandomized 
Allocation 
concealment 
Unclear Information not available 




Method Prospective, nonrandomized, multi-center study 
Participants From Jan 2007 through Aug 2009, 136 patients were enrolled 
Characteristics 
Gender 64% Male, 36% Female 
Median age 19 years (7-53 years) 
Original diagnosis Tetralogy of fallot 48% 
Aortic valve disease after Ross operation 21% 
Transposition of the great arteries 11% 
Truncus arteriosus 10% 
Double-outlet right ventricle 6% 
Valvar pulmonary stenosis 2% 
Other 1% 
79 
NYHA class I 16%, II 67%, III 16%, IV 1% 




No 74%, single stent 17%, multiple stent 9%, no 
report 1% 





diameter at the 




Outcome Hemodynamic measures 
 Primary indication PR (n=65) Primary indication Obstruction 
or Mixed (n=59) 






















































Echocardiography, MRI, ECG  
Variable Pre Post (6 m) P 
80 
Echocardiography (n=98)    
RV pressure 73.5±17.9 55.0±14.6 0.001 




55.0±23.1 32.9±13.8 0.001 
MRI (n=80)    
RV end-diastolic 
volume 
205.8±90.2 172.7±76.3 0.001 
Indexed RV end-
diastolic volume 
125.1±49.2 103.0±39.5 0.001 
RV ejection fraction 43.2±14.1 42.6±12.3 0.9 
RV mass 67.3±27.3 57.5±19.3 0.001 
PR fraction 24.8±14.9 2.8±3.1 0.001 
Cochrane’s Risk of Bias 




No Described as nonrandomized 
Allocation 
concealment 
Unclear Information not available 
Blinding No Non randomized 
Secchi 2013 
Method Retrospective study (other information not available) 
Participants Jan 2008 to Jun 2010 in 27 consecutive patients 
Demographics 
Gender 12 females, 15 males 
81 
Age 22±9 years 
Original diagnosis 
 
Tetralogy of Fallot 26%, Aortic valve disease 
26%, transposition of great arteries 16%, 
double outlet right ventricle 11%, truncus 
arteriosus 7%, pulmonary atresia 7%, 
pulmonary stenosis 7% 
RVOT conduit 
type 
Homograft 41%, shelhigh 15%, matrix 11%, 
monoscupid homograft 7%, hancock 7%, 
contegra 4%, ionescu-shiley 4%, conduit not 
implanted 11% 
Intervention Melody pulmonary valve implantation 
Outcome Cardiac magnetic resonance data 
 Pre Post p 
RV EDVI 79±42 64±21 0.050 
RV ESVI 34±41 30±14 0.021 
RV EF 49±13 54±12 0.018 
LV EDVI 64±15 73±21 0.034 
LV ESVI 30±9 33±4 0.508 
LV EF 54±7 57±10 0.147 
RF 14±18 2±5 0.013 
PG 36±15 13±15 <0.001 
Cochrane’s Risk of Bias 








Unclear Information not available 




Method Prospective (other information not available) 
Participants Between Oct 2005 and Dec 2008, 28 adolescents 
Inclusion criteria 
RV systolic pressure >2/3 ysstemic with clinical symptoms or RV 
systolic pressure >3/4 of systemic with no clinical symptoms and/or 
Moderate to severe PI and 1 of the following – severe RV 
dysfunction, severe RV dialation, Decreased exercise capacity, 
arrhythmias 
RVOT dimentions <22X22 mm, RVOT dimentions >14 X14 mm, 
weight >20kg 
Exclusion criteria 
Age<5 yrs or weight <20 kg, pregnancy, occluded central veins, 




Gender Male 16, Female 12 
Primary 
Diagnosis 
PA/VSD 32%, TOF 25%, PAT 18%, DORV, 
TAG/PS 7%, AI 7%, ccTGA/PS 7%, AoA/VSD 4% 
Primary 
repair 
RV-PA conduit 61%, TAP 21%, Ross 4%, Ross-
Konno 4%, Yasui 4%, REV 6% 




Intervention MelodyTM valve implantation 
Outcome Cauterization data 
 Before PPVI After PPVI p 
RV-PA gradient, 
mmHg 
36±15 12±7 <0.001 
RVSp, mmHg 61±16 41±11 <0.001 
RVDp, mmHg 11±5 10±4 0.04 
MPAPs, mmHg 26±8 30±9 0.02 
MPAPd, mmHg 11±4 15±5 0.003 
AoPs, mmHg 86±10 94±11 0.001 
AoPd, mmHg 56±7 61±8 0.001 
RV/Ao 70±16 44±11 <0.001 
MRI Volumetric Data 
RVEDV 149±49 144±35 0.005 
RVESV 85±48 63±29 0.005 
RV effSV 44±12 48±8 0.04 
RVEF 42±15 46±13 0.43 
RV CO 2.7±0.5 3.4±0.8 0.04 
LVEDV 90±19 97±20 0.007 
LVESV 37±10 39±11 0.6 
LVEF 50±13 57±14 0.02 
LV effSV 56±9 60±7 0.24 
LV CO 2.7±0.6 3.2±0.6 0.02 
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RV/LVEDV 1.75±0.5 1.24±0.27 0.001 
PR 24±10 7±7 <0.001 
Notes  
Cochrane’s Risk of Bias 




No Described as nonrandomized 
Allocation 
concealment 
Unclear Information not available 




Appendix IV Abbreviation 
 
CHD  Congenital Heart Disease 
DORV  Double Outlet Right Ventricle 
MRI  Magnetic Resonance Imaging 
PA  Pulmonary Artery 
PPV  Percutaneous Pulmonary Valve 
PPVI  Percutaneous Pulmonary Valve Implantation 
RV  Right Ventricle 
RVOT  Right Ventricle Outflow Tract 
RVP  Right Ventricular Pressure 
RV-PA  Right Ventricle to Pulmonary Artery 
TA  Truncus Arteriosus  
TGA  Transposition of Great Arteries 




논 문 초 록  
 
 
경피적 폐동맥판 치환술은 2000년에 첫 시도되어 십여 년 동안 사용되어 
왔다. 본 연구는 경피적 페동맥판 치환술 이후 이의 임상결과에 대하여 
연구된 논문을 체계적 문헌고찰 및 메타분석 하는데 목표하였다.  
문헌검색은 PubMed와 Cochrane 데이터베이스를 사용하였으며, NECA 
가이드라인에 준하여 2014년 4월에 시행되었다. 599개의 문헌이 검색되었으며, 
이중 2005년 이후 출간된 10개의 문헌이 본 연구에 사용되었다. 메타분석은 
RevMan 소프트웨어를 사용하여 분석하였다.  
분석된 즉시적 혈류역학, MRI, 혈류역류에 대한 임상결과는 유의한 
유효성을 보여주었다. RV systolic pressure 는 유의하게 감소하였으며 (mean 
difference: 20.03mmHg, 95%: 17.95, 12.11), RV diastolic 도 유의하게 
감소하였고(mean difference: 1.69mmHg, 95%: 0.94, 2.26), RV-PA gradient 도 
유의한 감소를 보였으며(mean difference: 18.96, 95%: 15.94, 21.99), End-diastolic 
RV volume 또한 유의한 감소를 보였다 (mean difference: 26.92, 95%: 16.06, 
37.77).  
본 연구는 경피적 폐동맥판 치환술 이후의 안전성 및 유효성 개선의 
유의한 차이를 보였다. 
 
 
주요어 : 경피적 폐동맥판 치환술, 체계적 문헌고찰, 메타분석 
학 번 : 2011-23867 
